Home › a Keryx revenue falls short despite support of analysts, Baupost
 

Keywords :   


a Keryx revenue falls short despite support of analysts, Baupost

2015-08-05 20:24:17| Biotech - Topix.net

Boston-based Keryx Biopharmaceuticals has reported what it calls "progress" in the launch of its drug for dialysis patients, called Auryxia, in recent months, including expanded insurance coverage in the U.S., success in contacting potential prescribers and likely European approval in coming months. Keryx , which moved its headquarters to Boston last year from New York City, reported Auryxia sales of just $1.8 million in the second quarter since the drug's launch.

Tags: support short falls revenue

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 2
29.06Tropical Storm Beryl Public Advisory Number 2
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 2
29.06Tropical Storm Beryl Forecast Advisory Number 2
More »